Aequus Pharmaceuticals is a pharmaceutical company that focuses on therapeutic areas, including neurology, ophthalmology, and transplant.
Aequus Pharmaceuticals has raised $299K in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2023.
Aequus Pharmaceuticals's investors include Northview LifeSciences.
Aequus Pharmaceuticals is headquartered in Vancouver, Canada.
Aequus Pharmaceuticals is a pharmaceutical company that focuses on therapeutic areas, including neurology, ophthalmology, and transplant.
Aequus Pharmaceuticals is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aequus Pharmaceuticals — Funding & Investors." VCBacked, July 6, 2023, https://www.vcbacked.co/company/aequus-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2023). Aequus Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/aequus-pharmaceuticals
{{cite web |title=Aequus Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/aequus-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated